scholarly journals Primary Salivary Duct Carcinoma Arising from the Stensen Duct

2016 ◽  
Vol 95 (9) ◽  
pp. E15-E17 ◽  
Author(s):  
Kenji Noda ◽  
Takashi Hirano ◽  
Tomoyo Okamoto ◽  
Masashi Suzuki
Keyword(s):  
Computed Tomography ◽  
Neck Dissection ◽  
Clinical Course ◽  
Additional Treatment ◽  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Histologic Diagnosis ◽  
Duct Carcinoma ◽  
The Right

This report describes a salivary duct carcinoma (SDC) arising from the extraglandular portion of the Stensen duct. The patient was a 56-year-old man who presented with a palpable, elastic, hard mass without tenderness in the right cheek. Computed tomography revealed a tumor of the extraglandular portion of the Stensen duct. Supraomohyoid right neck dissection and total right parotidectomy were performed, and the histologic diagnosis was SDC of the Stensen duct. Postoperatively, the patient received no additional treatment. Neither recurrence nor metastasis was observed during 4 years of follow-up examination. SDC of the Stensen duct is extremely rare. To our knowledge, there is no report that describes primary SDC arising from that location. We also believe this is the first report that describes the clinical course of primary SDC arising from a Stensen duct.

scholarly journals Long-Term Recurrence-Free Survival After Salivary Duct Carcinoma of the Parotid: A 10-Year Follow-Up Case Report

2020 ◽  
pp. 1-3
Author(s):  
Peer W. Kämmerer ◽  
D. Schneider ◽  
Peer W. Kämmerer
Keyword(s):  
Radiation Therapy ◽  
Facial Nerve ◽  
Salivary Duct Carcinoma ◽  
Adjuvant Radiation ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Parotid Region ◽  
Parotid Neoplasm ◽  
The Right

Salivary duct carcinoma (SDC) represents a very rare and aggressive parotid neoplasm. A 70-year-old male was admitted to the hospital with a swelling of the right parotid region, persisting for twelve weeks. Based on sonography and contrast-enhanced computed tomography, a suspicious lesion showing mass expansion and invasion of surrounding tissues was seen. Intraoperative biopsy brought evidence of SDC. In accordance, surgical treatment included parotidectomy with preservation of the facial nerve as well as ipsilateral neck dissection due to suspicious lymphatic nodes. Afterwards, an adjuvant radiation therapy was undertaken. At 10 years of follow-up, the patient was alive and free of recurrence with full function of the facial nerve. In conclusion, keeping in mind its poor prognosis, the rare parotid salivary duct carcinoma needs aggressive therapy consisting of a surgical as well as a radiation therapy approach.

Salivary Duct Carcinoma with Unusual Clinical Course of Sialolithiasis

2014 ◽  
Vol 57 (4) ◽  
pp. 251
Author(s):  
Kyung Yeon Kim ◽  
Hae Sang Park ◽  
Sung Min Chung ◽  
Han Su Kim
Keyword(s):  
Clinical Course ◽  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Duct Carcinoma

scholarly journals Orbital metastasis from a primary salivary duct carcinoma: importance of long-term follow-up

2019 ◽  
Vol 54 (1) ◽  
pp. e21-e24
Author(s):  
Amar Pujari ◽  
Ritika Mukhija ◽  
Adarsh Shashni ◽  
Mandeep S Bajaj ◽  
Seema Sen
Keyword(s):  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Orbital Metastasis ◽  
Duct Carcinoma ◽  
Long Term Follow Up

scholarly journals HER2/neu negative salivary duct carcinoma of parotid: A case with forty months recurrence free follow up

2015 ◽  
Vol 8 ◽  
pp. 22-24 ◽  
Author(s):  
Sandhya Gokavarapu ◽  
Daphne Fonseca ◽  
Sreenivasa Puthamakula ◽  
Bal P. Reddy ◽  
B. Sridhar Reddy ◽  
...  
Keyword(s):  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Duct Carcinoma

Management of sarcomatoid salivary duct carcinoma of the submandibular gland duct with coexisting seropositive human immunodeficiency virus

2013 ◽  
Vol 127 (6) ◽  
pp. 621-624
Author(s):  
W F Mourad ◽  
K S Hu ◽  
R A Shourbaji ◽  
L B Harrison
Keyword(s):  
Computed Tomography ◽  
Submandibular Gland ◽  
Adjuvant Radiotherapy ◽  
Salivary Duct Carcinoma ◽  
Emission Tomography ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Positron Emission ◽  
Immunodeficiency Virus ◽  
Gland Duct

AbstractBackground:Sarcomatoid salivary duct carcinoma of the submandibular gland is extremely rare. This paper highlights the impact of surgery and adjuvant radiation therapy on the outcome of this disease.Methods:A 59-year-old man with human immunodeficiency virus presented with a painless, rapidly growing left neck mass. Biopsy followed by surgical excision of the left submandibular gland revealed sarcomatoid salivary duct carcinoma of the submandibular gland duct with perineural invasion and close margins, for which he underwent adjuvant radiotherapy. Post-operative positron emission tomography and computed tomography revealed no residual or metastatic disease. Pathological analysis of tumour–node–metastasis staging revealed a T2 N0 M0 (stage II) tumour.Results:The patient tolerated his treatment without serious acute or long-term side effects. There was no evidence of disease on comprehensive examination or on positron emission tomography or computed tomography scans at the 4.6-year follow up.Conclusion:Surgery followed by adjuvant radiotherapy provided practical locoregional control with acceptable toxicity. Further detailed case reports are warranted to optimise the management of this rare malignancy.

scholarly journals Long-term follow-up of ciliated muconodular papillary tumor of the lung by computed tomography: a case report

2020 ◽  
Vol 2020 (12) ◽  
Author(s):  
Ryohei Matsushima ◽  
Takeshi Mori ◽  
Sho Saeki ◽  
Hironori Hinokuma ◽  
Hidekazu Tanaka ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Clinical Course ◽  
Wedge Resection ◽  
Lower Lobe ◽  
Papillary Tumor ◽  
Ct Findings ◽  
Preoperative Ct ◽  
The Right

Abstract Ciliated muconodular papillary tumor (CMPT) is an extremely rare pulmonary tumor and the clinical characteristics are still unknown. We report the preoperative long-term clinical course and changes in computed tomography (CT) findings of CMPT. A 60-year-old man underwent lower bilobectomy for squamous cell carcinoma in the right lower lobe 18 years before the surgery for CMPT. Twelve years before the surgery for CMPT, a 4-mm small ground glass nodule arose in the left lower lobe. The nodule gradually grew and became dense over time. Because it became mostly solid with central cavities, the patient underwent wedge resection and the tumor was diagnosed as CMPT. There were no recurrences 20 months after surgery. The preoperative CT findings of CMPT were similar to progressive preinvasive lesion, whereas it followed the benign clinical course. To the best of our knowledge, this is the first report on long-term preoperative follow-up of CMPT.

scholarly journals Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma

2021 ◽  
pp. 343-346
Author(s):  
Tsuyoshi Sato ◽  
Takahiro Maeta ◽  
Ryosuke Abe ◽  
Hiroyuki Yamada ◽  
Kazuyuki Ishida ◽  
...  
Keyword(s):  
Immunohistochemical Analysis ◽  
Salivary Duct Carcinoma ◽  
Adjuvant Chemoradiotherapy ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Hilar Lymph Node ◽  
Metastatic Lesions ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
The Right

Salivary duct carcinoma (SDC) is a rare and highly aggressive malignancy. A 58-year-old man presented with a right-sided submandibular mass and metastatic lesions in the right supraclavicular and inferior internal jugular nodes. He underwent right submandibulectomy and right neck dissection followed by adjuvant chemoradiotherapy. However, relapse occurred in the hilar lymph node and lumbar spine. Although radiotherapy was performed, a second relapse appeared in the hilar lymph nodes and sacral bone. Immunohistochemical analysis revealed negativity for programmed death ligand-1 (PD-L1) in the primary tumor specimen. The patient then received the anti-programmed death-1 (PD-1) antibody nivolumab. His metastatic lesions were completely eliminated after 48 weeks of therapy. This case reveals that anti-PD-1 antibodies are effective even against PD-L1-negative SDC.

Salivary Duct Carcinoma Metastasizing to the Small Bowel

1996 ◽  
Vol 82 (5) ◽  
pp. 502-504 ◽  
Author(s):  
Božo Krušlin ◽  
Mira Ščukanec-Špoljar ◽  
Viktor Šeparović ◽  
Spomenka Manojlović ◽  
Dražn Janković ◽  
...  
Keyword(s):  
Small Bowel ◽  
Acute Appendicitis ◽  
Parotid Gland ◽  
Metastatic Tumor ◽  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
First Case ◽  
Prominent Symptom ◽  
The Right

We report a case of salivary duct carcinoma in a 47-year-old woman. The patient presented with symptoms simulating acute appendicitis. Surgery revealed metastatic tumor in the wall of the small bowel. Two months later, a tumor of the right parotid gland was resected, and histologic analysis revealed a salivary duct carcinoma. To our knowledge, this is the first case of salivary duct carcinoma metastasizing to the small bowel with manifestations of metastatic disease as the prominent symptom.

scholarly journals Salivary Duct Carcinoma: Case Reports and Brief Review of the Literature

2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Deepti Kantamani ◽  
Sai S. Bandaru ◽  
Jennifer L. Miatech ◽  
M. Patrick Stagg
Keyword(s):  
Neck Dissection ◽  
Adjuvant Radiotherapy ◽  
Case Reports ◽  
Salivary Duct Carcinoma ◽  
World Health ◽  
High Morbidity ◽  
Adjuvant Radiation ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Total Parotidectomy

Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,000 patients. Standard treatment for SDC is wide surgical resection along with lymph node dissection followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is not known. In this report, we present three cases of SDC. A 71-year-old female with T1N0M0 disease was treated with total parotidectomy, ipsilateral neck dissection, and adjuvant radiotherapy without evidence of disease recurrence at 5 months. The second is a 59-year-old female with TXN1M0 disease who was treated with total parotidectomy with ipsilateral level I-IV neck dissection and adjuvant radiotherapy without evidence of disease occurrence at 21 months. The third case is a 79-year-old male with widely metastatic disease, including brain metastases, treated with cranial irradiation, leuprolide, and lapatinib who remains under home hospice care.

Tumor-Infiltrating Lymphocytes and Programmed Death-Ligand 1 Expression in Salivary Duct Carcinoma

2019 ◽  
Vol 152 (Supplement_1) ◽  
pp. S40-S41
Author(s):  
Kyriakos Chatzopoulos ◽  
Andrea Collins ◽  
Joaquin Garcia
Keyword(s):  
Tumor Infiltrating Lymphocytes ◽  
Salivary Duct Carcinoma ◽  
Rank Test ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Exact Test ◽  
Log Rank Test ◽  
Programmed Death ◽  
Infiltrating Lymphocytes

Abstract Objectives Salivary duct carcinoma is a rare high-grade salivary gland tumor, sharing common features with invasive ductal carcinoma of the breast—particularly apocrine type. Increased density of tumor-infiltrating lymphocytes (TILs) is a favorable prognostic factor in many solid tumors and has been correlated with elevated expression of programmed death-ligand 1 (PD-L1), a targetable molecule. We investigated the prognostic role of TILs and PD-L1 expression in salivary duct carcinoma. Methods Clinical records and archived surgical pathology material were evaluated from 28 patients with a diagnosis of salivary duct carcinoma at Mayo Clinic Rochester (between 1961 and 2007). TILs were evaluated on hematoxylin and eosin–stained slides and reported as continuous variables. Immunohistochemistry for PD-L1 (clone 22C3) was performed on unstained slides and evaluated using the Combined Positive Score (CPS). Fisher’s exact test was used to assess frequency distribution differences. Log-rank test and Cox proportional hazards model were used to assess the impact of the variables on survival. Results Twenty-eight patients had salivary duct carcinoma (age range 35-87, mean 61), and follow-up averaged 60 months (range 6-252 months). At the end of the follow-up period, 22 patients (79%) had died of salivary duct carcinoma, while remaining patients were alive (4.14%) or had died of other causes (2.7%). For the entire follow-up period, levels of TILs of 40% or more were associated with favorable overall survival (log-rank test, P = .01) and were predictors of better survival in univariate analysis (hazard ratio: 0.18, P = .02). PD-L1 expression was not significantly different between the high and low TIL groups (Fisher’s exact test, P = .67). Survival analysis regarding PD-L1 expression did not yield statistically significant results (log-rank test, P = .74; hazard ratio: 0.87, P = .74). Conclusion High TIL levels, but not PD-L1 expression as determined using the CPS, predict better survival in patients with salivary duct carcinoma.

Sign in / Sign up

Export Citation Format

Share Document